Semaglutide and kidney function: friends or enemies?

Published: 5 February 2024
Abstract Views: 525
PDF: 281
HTML: 240
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RAs) approved for the treatment of type 2 diabetes mellitus (T2DM) and chronic weight management in obesity. GLP-1RAs are being investigated to slow the decline of kidney function in type 2 diabetics with chronic kidney disease. These agents prevent renal complications and have proven beneficial effects on cardiac outcomes. We describe a rare case of semaglutide-induced acute kidney injury (AKI) in a young woman with obesity, T2DM, hypertensive cardiomyopathy, and no pre-existing chronic kidney disease (CKD). This case is relevant as GLP1-RAs is used frequently in patients with and without kidney disease. Currently, only 3 cases of AKI ascribed to semaglutide of which only 1 without CKD have been described. Only in this case, kidney function improves after semaglutide discontinuation. However, because GLP1-RAs will be prescribed more and more frequently, we sought to highlight this possible, serious adverse effect of semaglutide.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab 2021;46:101102. DOI: https://doi.org/10.1016/j.molmet.2020.101102
Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002;87:1239-46. DOI: https://doi.org/10.1210/jcem.87.3.8355
Eng J, Kleinman WA, Singh L, et al. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from Guinea pig pancreas. J Biol Chem 1992;267:7402-5. DOI: https://doi.org/10.1016/S0021-9258(18)42531-8
Göke R, Fehmann HC, Linn T, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 1993;268:19650-5. DOI: https://doi.org/10.1016/S0021-9258(19)36565-2
Amaro A, Sugimoto D, Wharton S. Efficacy and safety of semaglutide for weight management: evidence from the STEP program. Postgrad Med 2022;134:5-17. DOI: https://doi.org/10.1080/00325481.2022.2147326
Pratley RE, Aroda VR, Lingvay I, et al. SUSTAIN 7 investigators. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol 2018;6:275-86. DOI: https://doi.org/10.1016/S2213-8587(18)30024-X
Rossing P, Baeres FMM, Bakris G, et al. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant 2023;38:2041-51. DOI: https://doi.org/10.1093/ndt/gfad009
Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab 2017;19:1242-51. DOI: https://doi.org/10.1111/dom.12932
Shetty R, Basheer FT, Poojari PG, et al. Adverse drug reactions of GLP-1 agonists: a systematic review of case reports. Diabetes Metab Syndr 2022;16:102427.
Advera Health Analytics. FAERS Adverse Event, Acute Kidney Injury, Glucagon-like peptide-1 (GLP-1) Analogues Classification Comparison Report. Evidex 2020.
Patoulias D, Boulmpou A, Papadopoulos CE, Doumas M. Glucagon-like peptide-1 receptor agonists and the risk of acute kidney injury: alarming, or not? Kidney Med 2021;3:674-5. DOI: https://doi.org/10.1016/j.xkme.2021.02.014
Shetty R, Basheer FT, Poojari PG, et al. Adverse drug reactions of GLP-1 agonists: A systematic review of case reports. Diabetes Metab Syndr 2022;16:102427. DOI: https://doi.org/10.1016/j.dsx.2022.102427
Leehey DJ, Rahman MA, Borys E, et al. Acute Kidney Injury Associated With Semaglutide. Kidney Med 2021;3:282-5. DOI: https://doi.org/10.1016/j.xkme.2020.10.008
Borkum M, Lau W, Blanco P, Farah M. Semaglutide-Associated Acute Interstitial Nephritis: A Case Report. Kidney Med 2022;4:100561. DOI: https://doi.org/10.1016/j.xkme.2022.100561
Perazella MA, Markowitz GS. Drug-induced acute interstitial nephritis. Nat Rev Nephrol 2010;6:461-70. DOI: https://doi.org/10.1038/nrneph.2010.71

How to Cite

Giofrè, F., Trapanese, V., Natale, M. R., Vatalaro, C., Cosentino, F., Melina, M., Pelle, M. C., Carullo, N., Capria, M., & Arturi, F. (2024). Semaglutide and kidney function: friends or enemies?. Italian Journal of Medicine, 18(1). https://doi.org/10.4081/itjm.2024.1694

List of Cited By :

Crossref logo